Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Would you recommend hypofractionated treatment for early stage, bilateral breast cancers?
Assume each primary meets ASTRO 2018 guidelines
Answer from: Radiation Oncologist at Community Practice
yes as i don't see any reason and have done multiple times
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
Agreed, key is to ensure fields are set up to prevent any potential overlap
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
Yes, check for overlap. Otherwise, there is no glaring contraindication.
Sign in or Register to read more
4383
4395
4397
Related Questions
How would you treat a young breast cancer patient with limited nodal involvement and an isolated sternal oligometastasis at diagnosis?
What is your preferred method of surveillance after mastectomy?
Would you offer ultrahypofractionated 5-fraction whole breast only for a women with ER-/HER2+/cN+ disease with pCR following neoadjuvant systemic therapy?
In patients with history of prior axillary surgery, subsequently with breast cancer recurrence, and sentinel lymph nodes mapped to internal mammary area (but were not biopsied), do you offer post-mastectomy radiation to cover the IMNs?
For patients between 40-49 years old who undergo lumpectomy, how do you choose between offering PBI per the updated PBI guidelines or boosting based on boost guidelines?
How do you approach reirradiation in a patient who underwent breast-conserving surgery for recurrent breast cancer after initial lumpectomy and APBI?
How would you treat a patient with HER2 positive CNS only progression on fam-trastuzumab which had previously progressed on tucatinib/capecitabine/trastuzumab, and has failed both SRS and WBRT?
Does the presence of LCIS on pathology in a patient with IDC impact your decision to offer APBI?
How do you weigh upfront nodal burden when deciding to omit PMRT in a patient with cN1, ypN0 disease after neoadjuvant chemo, mastectomy and ALND?
Do you recommend high ozonated oil for radiation dermatitis?